HOME > BUSINESS > Biocon unit Syngene Intl gets FIPB approval for IPO

Biocon unit Syngene Intl gets FIPB approval for IPO

Syngene_2

Syngene International, an India-based Contract Research Organisation and a subsidiary of Biocon Ltd, announced that it has received the Foreign Investment Promotion Board (“FIPB”) approval for raising the foreign investment to 44% from the earlier approved 10% by way of its Initial Public Offering (“IPO”).

The IPO is an offer for sale (“OFS”) by Biocon of a part of its shareholding in Syngene. The Biocon Group presently holds 83.6% equity stake in Syngene.

Commenting on the development, Peter Bains, Chief Executive Officer, Syngene International, said, “We are happy to receive the FIPB approval to increase the foreign investment limit in our company. Syngene supports the global pharmaceutical, biotech and life science industries; this approval will enable us to look to broaden our global investor base.”

Syngene reported revenues of Rs 7,077 million for FY 2013-14 and Rs 6175 million for 9 month ended 31st December 2014. For the three fiscal years ended March 31, 2014, its total revenue, restated profit and EBITDA grew at compounded annual growth rates (“CAGR”) of 29.9%, 70.5% and 30.6%, respectively.

Its flexible business models, expertise in managing large integrated collaborations and world-class infrastructure has not only helped it renew and expand its existing client collaborations but also in attracting new clients. Syngene’s client base increased 90% from 103 in FY 2012 to 195 as on 31st December 2014.

It has long term multi-disciplinary partnerships with three of the world’s leading global healthcare organisations, Bristol-Myers Squibb Co. (“BMS”), Abbott Laboratories (Singapore) Pte. Ltd. and Baxter International Inc. and has set up dedicated R&D Centres for each of them. The dedicated R&D Centre of BMS is its largest R&D presence in Asia with more than 400 scientists.

On January 12, 2015, Biocon Research Limited (a wholly owned subsidiary of Biocon) transferred a 10% stake in Syngene to IVF Trustee Company Private Limited for a consideration of Rs. 3,800 million.

Follow ULTRA.news
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash."We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences.Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab."Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions.The applications were resubmitted last mo...
Dr Reddy’s says EU approves production at Duvvada plant in Andhra Pharma major Dr Reddy's Laboratories said European Union authorities have again allowed it to produce drugs for sale in the EU region at its Duvvada factory in Andhra Pradesh.In its inspection conducted in September, the Regulatory Authority of Germany (Regierun von Oberbayer...
Reliance Capital’s general insurance unit IPO draws nearer Reliance Capital, the financial services arm of the Anil Ambani Group, said the Securities and Exchange Board of India (SEBI) issued its final observation letter to the draft red herring prospectus filed by its general insurance unit.The group had recently seen the successf...
Panacea Biotec gets US nod for generic version of cancer drug Abraxane Panacea Biotec said it got the regulatory nod in the US for launching a generic version of big-selling cancer drug Abraxane.The drug will be sold with the help of Canadian pharmaceutical distributor Apotex.The annual sale of Abraxane worldwide is approximately US$973.4 m...
Dr Reddy’s gets served with class action lawsuit Pharma major Dr Reddy's Laboratories said it has been served with a class action lawsuit, originally announced in August, related to public disclosures made about regulatory action against the company."Further to our intimation dated August 28, 2017 with regard to US Securit...
Biocon launches colon cancer drug in India, priced Rs 24,000 Pharmaceutical company Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients a variety of cancers in India.The biosimilar -- or a drug that mimics a natural protein -- is useful in treating metastatic colorectal cancer and other types of lung, k...
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash."This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...
HDFC Standard Life IPO priced at upper end; Size Rs 8,695 cr Housing Development Finance Corporation Ltd or HDFC said the initial public offering of its life insurance unit HDFC Standard Life Insurance has been priced at the upper end of Rs 290 per share.The IPO will now mop up Rs 8,695 cr from the market.The shares were being off...
ICICI Bank to conduct IPO for broking arm ICICI Securities ICICI Bank, one of India's top banks, said it has decided to list its equity broking arm ICICI Securities."The board of directors of the bank today approved the sale of a part of its shareholding in ICICI Securities Ltd in an initial public offering by the company, subject t...
Biocon, Mylan apply again for EU approval for cancer drugs trastuzumab, pegfilgrastim Biocon said its partner Mylan has resubmitted the marketing application for two substances used to treat cancer -- trastuzumab and pegfilgrastim -- before European authorities after making changes to their production facilities.The drug applications before the European Medic...
Alembic Pharma buys US-based generics manufacturer Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.Orbit has "a team of eight highly experienced scientists," Alembic said, adding that the firm focuses ...
Lupin Q2 sales down 8%, PAT falls 31.3% Pharma major Lupin reported an 8% fall in Q2 revenue to Rs. 3,952 cr.Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter fell by 13% to 927 cr.Net profit was also down by 31.3% at Rs 455 cr in in the September quarter. The profit was high...
Cipla gets USFDA nod to launch kidney drug in the US Pharma giant Cipla said it received final approval to market a generic version of Genzyme’s kidney drug Renvela Tablets in the US.Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health.The approval...
Reliance Capital-Nippon AMC IPO to raise Rs 1,500 cr Reliance Capital said the IPO of its subsidiary Nippon Life Asset Management will open on Oct 25 and close on Oct 27, with a price band of Rs 247 to Rs 252 per share.The offer will raise about 1,500 cr, out of which about Rs 600 cr will go to the company and the remaining w...